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Regulation of gene expression by interferons
G.R. Stark, R.L. Friedman, M. McMahon, J.
Kelly, S.P. Manly, A. Brasnett, A. Porter & I.M.
Kerr
Imperial Cancer Research Fund Laboratories,
London, WC2A 3PX, UK.
We have isolated cDNAs corresponding to several
different mRNAs induced by a-interferon (IFN) in
human cells. Two code for metallothionein II (MT
II) and a class I HLA; the others code for proteins
of unknown sequence. The levels of all the mRNAs
increase 5- to 40-fold about 1 day after treatment
with IFN. Synthesis of new proteins is not required
for induction. In IFN-resistant Daudi cells which
retain IFN receptors, MT II, HLA and 2-5A
synthetase mRNAs are induced normally, but
several of the others are not induced. It seems likely
that there are at least two pathways for induction,
possibly reflecting a diversity of receptor function.
In HeLa cells, most of the mRNAs are induced
both by x- and y-IFNs, but at least one is
preferentially induced by oa-IFN. The mRNA for
c-myc decreases in response to a-IFN but increases
in response to y-IFN. Thus, the control of IFN-
inducible mRNAs is complex. The rate of
transcription of the 1-8 mRNA, measured in
nuclear run-off experiments, doubles 5 min after
treatment with IFN, reaches a maximum by 60min,
and falls to the uninduced rate by 8-12h.
Activation of transcription also plays a major role
in increasing the levels of MT II and HLA mRNAs
in IFN-treated cells. In addition, from parallel
measurements of rates of mRNA accumulation and
transcription, it is clear that post-transcriptional
events are also important in increasing the levels of
IFN-induced mRNAs. When regions upstream of
the human genes for MT II, 2 class I HLAs and
one class II HLA are compared, a homologous
sequence of 15 base pairs is revealed. Similar
sequences have also been found near the 5' ends of
IFN-induced mouse genes. The functions of these
sequences are being characterised. The IFN-
regulated human 6-16 gene, transfected into mouse
cells, can be induced by mouse IFN. Therefore, it
should be possible to conduct a detailed analysis of
the promoter region.
Interferon and HLA expression
M. Fellous & F. Rosa
Department ofImmunology, Pasteur Institute, 25,
Rue du Dr. Roux, 75724 Paris Cedex 15, France
Interferon (IFN) enhances cell surface levels of
HLA class I and II histo compatibility molecules as
well as f2 microglobulin.
This increment follows the enhancement of the
corresponding messenger RNA in the cytoplasm of
cells analysed. Using isolated nuclei which allows
direct quantification of the transcription rate of
defined genes, one could show that IFN-,B and y
enhance the transcription rate of HLA class I and
fl microglobulin gene in a 3-4-fold ratio after 1 h
of treatment. The enhanced transcription is
maintained for at least 24h. The transcription of
HLA class II genes has also been analyzed.
Interferon y appears to act as specific inducer of
HLA class II genes.
Genetic control of IFN ,B and y receptor has also
been studied.
Finally the biological significance of HLA
interferon regulation was discussed.
The Macmillan Press Ltd., 1986
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Early and late events in the regulation of tumour cell
proliferation by interferons
M.J. Clemens, R. Exley, V.J. Tilleray & N. Sharp
Cancer Research Campaign Mammalian Protein
Synthesis and Interferon Research Group,
Department ofBiochemistry, St. George's Hospital
Medical School, London SW17 ORE, UK.
A wide variation is observed in the sensitivity of
both normal and tumour cells to the growth
inhibitory and differentiation-inducing effects of
interferons. In addition to possible differences in
the levels of interferon receptors, such variation
may be due to the nature of the signals generated
by these receptors and in the responses to these
signals of the cellular machinery involved in RNA
and protein synthesis and in DNA replication. The
key to understanding the molecular basis of cellular
growth regulation by interferons lies in identifying
the early signals and relating them to the
subsequent changes which occur in gene expression,
protein accumulation and DNA synthesis.
Our laboratory has concentrated on a detailed
analysis of the changes in macromolecular synthesis
which accompany interferon-induced impairment of
cell proliferation. In the highly sensitive Burkitt
lymphoma cell line, Daudi, growth inhibition is
characterized by a decline in the rate of protein
synthesis which does not involve the same
mechanisms of translational control as those
implicated in development of the interferon-
mediated antiviral state. In parallel with the
inhibition of protein synthesis, DNA replication is
impaired by a mechanism which appears to involve
deficient assembly of chromatin and instability of a
substantial fraction of the newly replicated DNA.
The relationships of these and other long-term
changes to the more rapid effects of interferons,
such as induction or repression of specific genes,
modulation of cellular responses to growth factors,
and changes in cellular or viral oncogene activity,
are not yet understood.
Interferons as immunomodulators
M. Moore
Department ofImmunology, Paterson Laboratories,
Christie Hospital and Holt Radium Institute,
Manchester, M20 9BX, UK.
In addition to the induction of new RNA and
protein and the inhibition of viral replication, the
interferons (IFNs) can influence a multiplicity of
cell types and functions. Since the cells of the
immune system are among those so influenced,
IFNs have been assigned an immunoregulatory
role. IFN-y (immune IFN) plays an important part
in the cascade of lymphokines generated during the
adaptive immune response. Antigen-stimulated T
cells produce IFN-y which in turn affects the
responsiveness of T cells and is involved in the
cooperation between T and B cells by acting as a
B-cell maturation factor. In addition, IFN-y acts on
the effector cells of the non-adaptive host response
regulating proliferation, differentiation and
function. Some of the effects of IFN-y are common
to all types of IFN, but others are predominantly
mediated by IFN-y. Most of the multicellular
effects of IFNy, unlike those of IFN/f/# are
stimulating, rather than inhibitory, activating new
genes. A recently recognised characteristic of IFN-y
is its ability to act synergistically with other factors
or cellular inducers. Some effects may not depend
entirely on IFN-y per se but are possibly secondary
to the IFN-y-induced expression of surface
receptors for other factors or regulatory substances.
Studies of IFN-y contribute to our understanding
of the regulation of the immune response and
inflammation and may assist in clarifying some of
the pathological processes involved in autoimmune
and other disorders. Exploitation of the synergy
between IFN-y and other cytokines could offer new
prospects for the therapeutic application of these
factors.
Properties of interferon-a2 analogues produced from
synthetic genes
V.E. Moore, R. Camble & M.D. Edge
ICI Pharmaceuticals Division, Mereside, Alderley
Park, Macclesfield, Cheshire, SKJO 4TG, UK.
We have shown that genes long enough to encode
interferon-al and interferon-ox2 can be synthesised
chemically and expressed in Escherichia coli. In
principle synthetic genes can be used to prepare
analogues with any genetically coded amino-acid
substituted at any number of desired positions
throughout the length of the polypeptide chain.
Using interferon-oc2 as a model system we have
been exploring the potential of this approach to
generate protein analogues for structure-activity
studies. Results to be presented illustrate that
coherent structure-activity patterns are obtained for
interferon analogues produced in this way. Some
20% of the sequence can be removed or extensively
substituted without any great change in biological
activity. Changes at just one or two residues
conserved among all human interferon-c and
interferon-# species can greatly decrease or abolishJOINT MEETING OF THE BACR & IACR 421
biological activity. A dipeptide sequence has been
identified which is critical for recognition by a
widely available monoclonal antibody. We are
convinced that the synthetic gene approach can
produce target analogues with the throughput
required to make useful progress in a protein
structure-activity programme.
Anticancer activity of interferons studied in animal
tumour models
F.R. Balkwill
Imperial Cancer Research Fund, Lincoln's Inn Fields,
London, WC2A 3PX, UK.
Successful use of biological response modifiers such
as interferons, (IFNs), in the therapy of cancer
requires an understanding of their mechanisms of
action. IFNs may act directly on tumour cells,
suppressing growth, altering differentiated state or
surface antigen expression, or by modulating host
responses to the tumour. Using the nude
mouse/human tumour xenograft model we have
found that human IFN-axs have a direct tumour
inhibitory effect with no modulation of the murine
host responses. Effects of IFN-cxs range from
complete regression, through tumour stasis to
progression at the same rate as control tumours
and are consistent for each individual tumour line.
Reasons for this difference are being investigated at
the membrane receptor and molecular level. Human
IFNs / or y have little or no antitumour activity in
this model system, but IFN-y stimulated levels of,
or induced de novo, Class II HLA and tumour-
associated antigens in some of the tumours, an
effect which may have relevance in man.
Mouse IFN also inhibited the growth of human
tumour xenografts, both resistant and sensitive to
HuIFN-a. Evidence so far would indicate that this
was not due to a direct effect on the human
tumour. Inhibition by murine IFN was also found
in beige (NK deficient) nude mice suggesting that
host NK cells were not involved in the inhibition.
This model system therefore provides evidence of
both direct and indirect effects of IFNs against
cancer.
Clinical and immunological studies of recombinant
interferon gamma (immuneronTM Biogen)
administered by 2 or 24 hour infusion in 30 patients
with metastatic melanoma
J.M. Kirkwood
For The Yale Melanoma Unit and Biogen, Inc.,
USA.
Thirty patients (pts) with advanced melanoma
entered a phase I/TI trial of IFNy at fixed dosages
of 3, 30, 300, 1000, or 3000pgm-2 d-1 x 14d
unless dose-limiting toxicity (DLT) was
encountered. IFN was administered either (a) by
continous 24h infusion or (b) by daily 2h infusion:
11 pts with objective response or stable disease
received maintenance IFNy at their original dosage
for 1-6 cycles (14d/42d) until progression of
tumour. Flu-like toxicity as with IFNa was seen in
all dosages over 3jugm 2 of IFNy. Neutropenia
(not DLT) was seen in all dosages over 30pgm 2:
hepatotoxicity was DLT in 4 pts at 1-3000pgm 2,
and rigors/malaise were DLT in 2 pts at
3000pgm 2. All toxicity was reversible after 24-
96h off IFNy. Complete response in lung disease
was seen at 3,g, and partial response in lung
disease at 300pgm 2 d-1; both were maintained
6 mos(sched.B). Nine other pts received 1-6 mos.
maintenance for stable/mixed responses. Serial
study of oligo 2' 5' A synthetase, natural killer
activity, and the phenotype of peripheral blood
mononuclear cell in these pts. has revealed schedule
and dose-dependent effects that are clustered in the
dosage ranges between 300 and 1000pgm-2 d-1 in
both schedules A and B.
Have interferons a clinical role in the management of
patients with cancer?
D. Crowther
Department ofMedical Oncology, Christie Hospital,
Wilmslow Road, Manchester M20 9BX, UK.
Although Interferon was discovered in the late
1950s by Isaacs & Lindenman, investigations of a
possible clinical role were not possible until about
20 years later. Early studies of anticancer activity
involved preparations from leucocytes with variable
purity and potency, however, the recent cloning of
human interferon genes and the application of
recombinant DNA technology has resulted in the
manufacture of pure forms of Interferon for clinical
trial. Initial enthusiasm for treating patients with
various forms of carcinoma has been tempered by
the realisation that recombinant Interferon alpha
used singly in current dose scheduling is of no value
in the management of the more common forms of
carcinoma (bronchus, breast, colorectal) but
responses in patients with certain B cell malig-
nancies have been more gratifying. 30-50% of
patients with low grade lymphomas respond to
Interferon alpha and in a series of previously
untreated patients from Manchester it has been
possible to postpone the necessity of using
damaging and potentially carcinogenic cytotoxic422 JOINT MEETING OF THE BACR & IACR
drugs for about one year. The use of Interferon
alpha in the treatment of patients with hairy cell
leukaemia has been even more successful and this
form of treatment is now first line therapy in the
medical management of these patients.
The future holds further promise since new
Interferons are now available for clinical testing
and already there are suggestions that some
patients with a particularly intractable malignancy
(renal cell carcinoma) can have a useful response to
Interferon gamma. The clinical role of com-
binations of bioregulators and their use in
conjunction with chemotherapy remains largely
unexplored but experimental studies indicate that
this is an important avenue for further investi-
gation. Phase I/II clinical trials of bioregulatory
molecules pose difficulties which are more apparent
than for cytotoxic drugs, since mechanisms of
action are less well understood and the desired
biological effect is unknown.
Abstracts of members'proffered papers
Induction and suppression of drug metabolizing
enzymes by interferon in the mouse
D.J. Adams', S. Seilman', J.D. Hayes2, F.
Balkwill2, B. Griffin3 & C.R. Wolf'
Imperial Cancer Research Fund 'Lab. Mol.
Pharmacology, Edinburgh, 2Interferon Lab, Lincoln's
Inn Fields, 3Department Clinical Chemistry,
University ofEdinburgh, UK.
The effect of murine interferon on drug
metabolizing enzymes in the mouse has been
studied because of the synergistic antitumour effects
observed when interferon and chemotherapy are
used in combination and also because of the
potential effects of viral infection on the activation
and deactivation of chemical carcinogens by these
enzymes. Antibodies against rat or human
glutathione transferases (GST) or cytochrome
P-450s, which cross-react with mouse, were used.
Western blots showed that proteins reacting with
antibodies to GST subunits Ya, and Ybi were
unchanged and those reacting with Yb2, Yc, Yf,
GST1 and GST2 were significantly suppressed.
Interestingly protein equivalent to GST A which has
been shown to be elevated in preneoplastic lesions,
was significantly elevated by interferon-treatment.
The metabolism of model GST substrates
substantiated these findings where some activities
were elevated, some unaffected and some
suppressed. Similar data were obtained using the P-
450 antibodies. A significant suppression of specific
mono-oxygenase activities followed interferon
administration.
Effects of human ac-2 interferon action on mutants of
African green monkey kidney cells transformed by
Simiian virus 40.
H. Shine & J.K. Collins
Virology Unit, Microbiology Department, University
College, Cork, Eire.
The CV-1 clone of African Green Monkey Kidney
Cells is the permissive host of choice for Simian
Virus 40 (SV40) replication. We have, using
nitrosoguanidine mutagenesis isolated mutants of
CV-1 cells which restrict SV40 replication. One
such mutant clone designated M6 has been selected
for this study. These cells have the following
properties:
(a) SV40 replication and cytopathic effect is
restricted on superinfection.
(b) They express intranuclear 94 K T as well as
two super T-antigens of 115 Kd and 125
Kdmol. wt.
(c) They contain very elevated levels of p53.
(d) They exhibit a transformed phenotype.
(e) They have integrated viral DNA.
(f) Wild type virus can be rescued at high
efficiency on fusion with permissive cells.
Using infectious centre assays and in situ blotting
we have found spontaneous release of low levels of
wt infectious particles indicating slight break-
through the mutant lesion. Using Sindbis virus
challenge we found that treatment of M6 cells with
10000 ml-' of a-2 interferon induced an
antiviral state. This level of treatment did not affectJOINT MEETING OF THE BACR & IACR 423
the expression of 94 Kd T or the two super T-
antigens. Interferon treatment however, did
eliminate the spontaneous production of low levels
of infectious virus found in untreated cells. Since
these cells contain 94 Kd T-antigen which is
refractory to interferon treatment interferon
inhibition of SV40 in these mutant cells must be
post transcriptional.
The induction of MHC antigens on rat tumours by
recombinant interferon-y.
H. Yeoman', R.A. Robins', R.W. Baldwin', P.H.
Van der Meide2 & H. Schellekens2
'Cancer Research Campaign Laboratories,
University ofNottingham NG7 2RD, UK, and
2Primate Centre TNO, Rijswijk, The Netherlands.
MHC encoded molecules play a pivotal role in the
induction and regulation of immune responses.
Interferons, most notably interferon-y, have been
shown to regulate MHC antigen expression. We
have looked at the effect of rat recombinant
interferon-y on MHC antigen expression in cell
cultures of a series of immunogenic and non-
immunogenic, spontaneous and chemically induced
rat tumours, by FACS analysis.
MHC class I can be augmented in 5/6 lines
tested. Mc7 is a chemically induced immunogenic
tumour that constitutively expresses high levels of
class I, which can be augmented by interferon-y to
give up to a 7-fold increase. Spl5 and Sp22 are
spontaneous non-immunogenic tumours that
constitutively express lower levels of class I than
Mc7, and can be augmented to express 3-4 times
the level of antigen. Sp4, a spontaneous
immunogenic tumour, expresses class I in vivo, but
loses this expression when cultured in vitro. Class I
expression is re-induced when the cell-line is
incubated with IFN-y. Induction of expression
occurs as early as day 1 and persists at these levels
until at least day 6. None of the tumours
constitutively express, or have been induced to
express, class II antigens, including the Y3
myeloma cell line.
The susceptibility of IFN-y treated tumour
targets to NK cytolysis has also been examined.
Mechanisms of antitumour activity of IFN-A/D
(BglI) on experimental metastases
P. Ramani, I. Hart, F.R. Balkwill
Imperial Cancer Research Fund, Lincoln's Inn Fields,
London WC2A 3PX, UK
A recombinant human hybrid alpha interferon
(rIFN-acA/D) with antiviral, anti-proliferative and
immunomodulatory effects on murine cells was
used to treat mice with experimental metastases.
There was significant inhibition of lung metastases
21 days after i.v. injection of 5 x 104 viable colon
carcinoma, Colo 26, cells in mice treated with
5OOng and 50ng daily 5 times a week. Similar
results were seen in normal BALB/c, nude BALB/c
and beige nude mice (NK cell deficient). Scheduling
experiments in vivo showed that the most
significant inhibition was seen when IFN was given
only for the first 5 days although statistically
significant reduction in lung tumour nodules and
lung weights was seen when IFN treatment was
initiated 7 days after the injection of tumour cells.
rHuIFN-aA/D was cytostatic to Colo 26 in vitro
causing 50% inhibition of cell growth or colony
number with dose comparable to levels achieved in
sera of mice. Although rHuIFN-aA/D stimulated
NK cell activity in BALB/c mice, Colo 26 cells
were resistant in vitro to NK cell lysis in both
control and treated mice. All these results suggest
that T cells and NK cells are not involved in the
antimetastatic action of rIFN-aA/D.
The relative importance of IFNs effects on
tumour cell proliferation, tumour cell surface
antigen expression, and host, macrophage activity
are currently being investigated. In this respect it is
of interest that although Colo 26 cells are resistant
to NK cells, they are lysed by activated
macrophages. Further studies with spontaneous
metastases of this tumour are also underway.
Effect of interferon on the activity of cytotoxic
agents in human lung cancer xenografts
R.J. Fergusson, L.E. Anderson & J.F. Smyth
Imperial Cancer Research Fund, Medical Oncology
Unit, Western General Hospital, Edinburgh, UK.
The effect of recombinant a2 interferon (IFN) on
the activity of cis-platinum (CP) and ifosfamide
(IFOS) was studied in human non small cell lung
cancer xenografts grown in CBA mice rendered
immunodeficient by neonatal thymectomy and total
body irradiation. Groups of 6-9 tumours were
randomised to single agent treatment, combination
therapy (CP+IFN or IFOS+IFN) or a control
group. IFN was injected s.c. in a dose of 2 x 104 IU
daily for 35 days. Drugs were given i.p. weekly
x 5 at 20% of MTD (CP 1.4 mg kg-1, IFOS
60mgkg-1). Tumours were measured three times
per week and volume estimated assuming an
ellipsoid shape. The median doubling time was
calculated for each group and the activity of each424 JOINT MEETING OF THE BACR & IACR
agent or combination was expressed in terms of the
specific growth delay (SGD) compared with
controls. IFN showed no activity as a single agent
(SGD<0.2) in these tumours. In a squamous
carcinoma the activity of CP and IFOS alone
(SGD=0.77 and 0.27) was increased by combina-
tion with IFN (SGD= 1.44 and 0.66). A similar
effect was seen in an adenocarcinoma (SGD for
CP=0.12, CP+IFN=0.48, IFOS=0.04, IFOS+
IFN=0.28) showing that IFN given in a dose which
produces no cytotoxic effect alone is able to
potentiate the effects of CP and IFOS in non small
cell xenografts.
The effect of recombinant y interferon on the
response to cytotoxic drugs of human lung cancer
cells in vitro
P.R. Twentyman, N.E. Fox & N.M. Bleehen
MRC Clinical Oncology and Radiotherapeutics Unit,
Hills Road, Cambridge CB2 2QH, UK.
A number of recent reports have indicated that, in
both in vivo and in vitro model systems, a or #
interferons can potentiate the cytotoxic or growth
inhibitory effects of anti-tumour drugs. Following
our studies of the effects of treatment with
recombinant y interferon (IFN-y) on the growth of
human lung cancer cells (Twentyman et. al, 1985,
Br. J. Cancer, 52, 21), we decided to investigate the
influence of IFN-y on the chemotherapy response
of such cells. We used 3 cell lines with markedly
different sensitivities to IFN-y. NCI-H69 is a small
cell line of low sensitivity, POC is a small cell line
of intermediate sensitivity and COR-L23 is a large
cell line of relatively high sensitivity. We have also
examined the effect of IFN-y on the drug response
of a multi-drug resistant variant of NCI-H69 and
the response to IFN-y alone of a multi-drug
resistant variant of COR-L23.
Using total cell number after 6-10 days as the
response endpoint, the sensitivities to adriamycin
(ADM), vincristine (VCR) and melphalan (MEL)
were generally found to be unchanged in the
presence of IFN-y at lkU ml-1 (NCI-H69 and
POC) or 200 U ml-1 (COR-L23). There was,
however, a small degree of sensitisation by IFN-y
of POC to ADM, of COR-L23 to MEL and a
small degree of protection of POC against VCR.
These findings are currently being further
quantified using clonogenic assay. Pretreatment of
POC with IFN-y for 48 h did not change the
subsequent response to a 1 h treatment with ADM,
VCR or MEL. A multidrug resistant variant of
COR-L23 was more sensitive to IFN-y alone than
the parent line.
Effects of recombinant interferon on the c-myc
oncogene product in daudi cells
J. Geradts & K. Sikora
Ludwig Institutefor Cancer Research, MRC Centre,
Hills Road, Cambridge, UK.
The growth of human lymphoblastoid cells in vitro
can be inhibited by interferon. It has previously
been shown that this antiproliferative effect is
accompanied by decreased transcription of the
c-myc gene, the cellular homologue of the avian
myelocytomatosis virus oncogene. As c-myc has
been widely implicated in carcinogenesis, we have
studied the modulation of the c-myc encoded
protein (p62C-Yc) by recombinant interferon. To
estimate p62C-myc levels, we used a recently
developed monoclonal antibody raised against
synthetic peptide fragments of this protein. Our
experiments suggest that, in Daudi cells whose
growth is arrested by interferon, p62C-mYc levels are
up to 75% lower than in control cells. There was
correlation between the amount of c-myc encoded
protein per cell and its proliferative status. Whether
the reduction in the c-myc protein is the cause or
consequence of the growth arrest induced by
interferon is as yet unclear.
Newly replicated DNA exhibits increased sensitivity
to nuclease digestion in Burkitt lymphoma (Daudi)
cells treated with human interferons
R. Exley & M. Clemens
Cancer Research Campaign Group, Department of
Biochemistry, St. George's Hospital Medical School,
London SWJ7 ORE, UK.
In Daudi cells, during inhibition of proliferation by
human interferons, DNA synthesis becomes
partially uncoupled from cell division. There is no
accumulation of DNA in these cells but rather a
rapid turnover of up to 50% of the newly
synthesized DNA. This could be due either to
increased cellular nuclease activity towards nascent
DNA chains or to a greater susceptibility of newly
replicated DNA to nucleases.
When control cells are labelled with 3H-
thymidine and isolated nuclei are prepared, it can
be shown that newly synthesised chromatin
undergoes a series of structural changes which alter
its sensitivity to micrococcal nuclease in vitro.
Initially, newly labelled DNA is preferentially
protected from digestion, perhaps because of
association of replication forks with the nuclear
matrix. Within 5-10 min this DNA transientlyJOINT MEETING OF THE BACR & IACR 425
becomes more nuclease-sensitive, as the chromatin
undergoes structural maturation. Within 20 min,
the DNA-- acquires the nuclease-resistance
characteristics of bulk parental chromatin. In
contrast, in interferon-treated Daudi cells both at
early and late times of labelling, the DNA in
isolated nuclei shows increased susceptibility to
nuclease digestion, suggesting that it is less
protected by its association with histones or other
proteins found in mature chromatin. No difference
is observed in the nuclease sensitivity of bulk
chromatin between control and interferon-treated
cells, as measured by digestion of DNA labelled for
2 h, and normal nucleosome ladders are observed
on agarose gel electrophoresis of the digestion
products. These results suggest that DNA turnover
in interferon-treated Daudi cells may be a
consequence of defective assembly of newly
replicated DNA into mature chromatin, perhaps
because of an impairment in chromatin protein
synthesis.
Changes in cellular phenotype of Burkitt lymphoma
(Daudi) cells associated with interferon-induced
growth inhibition
M. Clemens', R. Exley' & P. Knox2
'Cancer Research Campaign Group, 2Department Of
Biochemistry, St. George's Hospital Medical School,
London SW17 ORE, UK.
When Daudi cells are treated in culture with
concentrations of human interferons within the
physiological range, cell proliferation is inhibited
and ceases completely after 2-3 days. The response
is initially reversible and non-cytotoxic, but after 4-
5 days cell viability decreases, possibly due to the
inability of the cells to grow. Along with the
changes in macromolecular synthesis described
elsewhere there are modifications of cellular
behaviour and surface properties suggestive of a
'less transformed' phenotype.
The cells become larger in size, although their
DNA content does not increase. Analysis on a cell
sorter indicates an incomplete accumulation in the
GI phase of the cell cycle. When placed in 5-10%
serum-containing medium, interferon-treated Daudi
cells show a marked enhancement of adhesion to
tissue culture surfaces compared to control cells.
This effect, which is similar to that seen with a
variety of cell types after interferon treatment, can
also be elicited by treatment with the phorbol ester
TPA as well as by sodium butyrate and other
inducers of cell differentiation. These results are
compatible with the view that interferon treatment
initiates a series of changes in expression of genes
in Daudi cells which regulate not only cell
proliferation but also affect plasma membrane
properties and cytoskeletal organization. The latter
changes may reflect partial differentiation of these
transformed pre-B cells towards a state in which
they show less tumourigenic and/or metastatic
potential. Interferon-induced changes in the levels
of receptors for exogenous growth or differentiation
factors may be important in effecting this response.
Regulation of protein synthesis in growth inhibited
Burkitt lymphoma (Daudi) cells treated with human
interferons
V. Tilleray & M. Clemens
Cancer Research Campaign Group, Department Of
Biochemistry, St. George's Hospital Medical School,
London SW17 ORE, UK.
Inhibition of proliferation of Daudi cells by human
interferons is accompanied by a progressive
decrease in the rate ofcellular protein synthesis. We
have investigated whether the mechanisms which
control translation in interferon-treated, virus-
infected cells are also responsible for the inhibition
of protein synthesis in these uninfected cells.
The rate of polypeptide chain initiation is lower
in interferon-treated Daudi cells relative to control
cells, as indicated by a disaggregation of
polyribosomes. This does not appear to be due to
any inhibition of initiation factor eIF-2 activity
since the ability of this factor to form [elF-
2.GTP.Met-tRNAf] complexes or to bind Met-
RNAf to native 40S ribosomal subunits in extracts
from the cells remains unimpaired. There is also no
change in the phosphorylation state of eIF-2 in
Daudi cells following interferon treatment. No
major decrease in the content of total mRNA in the
cells can be observed up to 4 days of interferon
treatment, as judged by the poly(A) content of
purified cellular RNA and by the translatability of
mRNA in cell extracts added to an mRNA-
dependent reticulocyte lysate protein synthesizing
system. Thus neither the dsRNA-activated eIF-2
protein kinase pathway (which would inactivate the
initiation factor) nor the 2'5' oligoadenylate-
ribonuclease L pathway (which should inactivate or
destroy cellular mRNA) appear to be involved in
this system. Rather, there may be a block in
polypeptide chain initiation at the level of mRNA
binding to ribosomes to form functional 80S
initiation complexes. These possibilities are
currently under investigation.426 JOINT MEETING OF THE BACR & IACR
Enhancement of tumour cell malignancy by treatment
with chemotherapeutic agents
T.J. McMillan, J. Rao & I.R. Hart
ICRF Laboratories, Lincoln's Inn Fields, London,
WC2A 3PX, UK.
This study was undertaken to determine whether
anti-cancer drugs, many of which are carcinogenic
and mutagenic, could facilitate or promote tumour
progression. Cells from the B16-Fl subline of the
murine B16 melanoma were pre-treated with
hydroxyurea, methotrexate or cytosine arabinoside
prior to i.v. injection into groups of syngeneic mice
in a series of individual experiments. Three weeks
after injection mice were killed and the metastatic
burden was evaluated by counting the number of
lung tumour nodules. Treatment with all three
agents brought about increases in metastatic
capacity. Thus injection of 5 x 104 Fl cells pre-
treated for 18 h with 0.1 mM or 0.3 mM
hydroxyurea resulted in median numbers of 35
(range 19-72) and 31 (range 8-46) lung nodules
respectively compared to the 2 (range 0-6) resulting
from control cells. Similar results were achieved
with nude mice. Incubation for 48 h with 500 nM
or 750 nM methotrexate increased resultant lung
tumour colonies from a median of 9 (range 2-27)
to 30 (range 5-65) and 31 (range 15-52) respectively
while 18 h incubation in 100 ng ml-1 or 300 ng
ml-' cytosine arabinoside produced 38 (range 15-
56) and 5 (range 0-14) lung nodules respectively
compared with 6 (range 1-9) for untreated controls.
Treatment with all but the highest dose of cytosine
arabinoside brought about a significant increase
(P<0.05) in the metastatic abilities of these tumour
cells and these results suggest that certain anti-
neoplastic agents may play a direct role in
facilitating tumour progression. Some of the factors
which might be involved in this phenomenon, such
as mutagenicity, alterations in NK cell sensitivity
and cell cycle synchronisation have been examined.
Biodistribution and tumour imaging characteristics of 131, 123I and "'In-labelled monoclonal antibody in
mice with human tumour xenografts
M.V. Pimm', A.C. Perkins2 & R.W. Baldwin'
'Cancer Research Campaign Laboratories,
University ofNottingham, 2Medical Physics,
University Hospital, Nottingham, UK.
Monoclonal antibodies against human tumour
associated antigens, radio-labelled with 1311, 1231 or
1"lIn, are being evaluated for tumour imaging.
Each of these radionuclides had different energies
of y-emission which will affect the quality of the
images. In addition the radiometal III1n will have a
different biodistribution from that of radioiodide
following antibody catabolism. This would also
affect the imaging characteristics of the preparation.
In the present study the biodistribution of 1311, 1231
and "'1In from labelled antibody (791T/36) have
been compared in mice with human tumour
xenografts.
Blood levels of radioiodine and "'1In-labelled
antibody were similar in relation to injected doses.
However, whole body retention of 111In was over
twice that of radioiodine because radioiodide was
excreted but 11'In was retained. Consequently, in
relation to the whole body, blood levels of "11In
were lower than those of radioiodide. Xenograft
localisation of 1311 and 1231 was virtually identical
but the proportion of the injected dose of "11n
accumulated in tumour was up to five times higher.
Higher levels and longer retention of "'1In gave
tumour to blood ratios up to eight times those with
1311 or 1231. Gamma scintigraphy of tumour
xenografts with 123I-labelled antibody was superior
to 1311 due only to its lower energy of y-emission.
The energies of emission of "11In are higher than
1231, but superior tumour localization of "'1In
produced markedly better images than 123I-labelled
antibody.
These studies indicate that the superiority of
"'1In as a radiolabel for antibody imaging of
tumours is due as much to its physiological fate as
to its physical characteristics.
Enzymic fragmentation of monoclonal antibodies to
human tumour associated antigens: Biodistribution
studies with F(ab')2 and Fab in mice with human
tumour xenografts
S.M. Andrew', L. Dale1, M.V. Pimm', A.C.
Perkins2 & R.W. Baldwin'
'Cancer Research Campaign Laboratories, 2Medical
Physics, University ofNottingham, UK.
Monoclonal antibodies against human tumour
associated antigens are being evaluated for both
radioimaging of tumours and targeting of
therapeutic agents. F(ab')2 and Fab fragments may
give greater tumour discrimination than intact
antibody. In the present study the response of three
monoclonal antibodies to enzyme treatment has
been assessed and the tumour localization
characteristics of their fragments determined.
Papain treatment of 791T/36 (IgG2b) yielded Fab
fragments. 1251 labelled Fab localized in humanJOINT MEETING OF THE BACR & IACR 427
tumour xenografts more rapidly than intact
antibody but whole body survival of Fab was
shorter than intact antibody. Digestion of 791T/36
failed to yield F(ab.'), and fragments corresponding
predominantly to Fabc were obtained in very low
yield. With two anti-CEA antibodies (C/24 and
161, both IgGi) Fab and F(ab')2 fragments were
obtained. 1251 Fab and F(ab')2 localized in
xenografts more quickly than intact antibody.
Higher tumour to blood (T:B) ratios were seen
with fragments (T:B= 10:1) than with intact
antibody (T:B=3:1). However, whole body
survivals of Fab and F(ab')2 (t1/2 =8 h and 14h
respectively) were shorter than intact antibody (t1/2
=75h) and this produced lower absolute levels in
tumour. Gamma scintigraphy with 131I labelled
fragments gave earlier and superior imaging of
tumours than did 13II-intact antibody but this was
most marked with the Fab fragment.
Generally fragments do give more rapid and
superior tumour localisation than intact antibody,
and this gives more favourable gamma camera
imaging. Absolute levels in tumour are lower than
with intact antibody and this should be appreciated
in considering conjugates of fragments and drugs
for targeted therapy.
Preliminary evaluation of monoclonal antibodies to
oncogene products as drug-targeting vectors
M.J. Embleton', M.C. Garnett1, N.A. Habib2 &
C. Wood2
'Cancer Research Campaign Laboratory, University
ofNottingham, Nottingham NG7 2RD and
2Department ofSurgery, Royal Postgraduate
Medical School, London W12 OHS, UK.
Monoclonal antibodies to p28Ss' and p2l"as have
been studied as potential anti-tumour drug-
targeting agents using a panel of cultured human
tumour cell lines. Both antigens were detected at
the cell membrane by immunofluorescence on fixed
cytocentrifuge preparations, virtually all cells
exhibiting strong staining. Viable cells in suspension
or cytocentrifuge preparations fixed after staining
were largely negative, <5% of cells showing
fluorescence. This was confirmed by flow
cytofluorimetry, which gave a high signal for fixed
cells but a low signal for viable cells. These results
are consistent with the distribution of the oncogene
products on the inside of the cell membrane rather
than the outside.
Anti-p21las was linked to human serum albumin
conjugated to rhodamine in order to determine the
internalisation potential of anti-p21las vectored
compounds into cultured tumour cells. The anti-
p2lTas conjugate showed minimal surface binding
and only trace amounts of rhodamine appeared in
the cytoplasm over 4 h incubating at 37°C. By
comparison, a similar conjugate prepared with
another antibody, 791T/36, resulted in strong
cytoplasmic labelling in the perinuclear area. A
drug conjugate prepared by linking anti-p21las to
methotrexate-substituted human serum albumin
(MTX-HSA) was only marginally more cytotoxic to
tumour cells than MTX-HSA alone, and 50-100
times less toxic than free methotrexate. In
comparison, a similar conjugate prepared with the
same batch of MTX-HSA but antibody 791T/36
was highly toxic to relevant target cells.
Monoclonal antibodies to oncogene products do
not appear to be suitable as anti-tumour targeting
agents.
Is production of human chorionic gonadotrophin
(hCG) or alpha fetoprotein (AFP) by somatic
tumours a marker ofchemosensitivity?
S.M. Crawford, J.A. Ledermann, G.J.S. Rustin,
R.H.J. Begent, E.S. Newlands & K.D. Bagshawe
Department ofMedical Oncology, Charing Cross
Hospital, London W6 8RF, UK.
Some tumours of somatic origin have elements
within them which produce markers which are
associated with germ cell or gestational
trophoblastic tumours. This biochemical behaviour
may be associated with trophoblastic differentiation
on histology. In our laboratory, hCG is elevated in
19.6% of samples from patients (pts) with upper
gastrointestinal (GI) tumours and 19% from those
with bladder tumours. (AFP 14.4% and 13%
respectively.) We have treated 7 pts with GI and
bronchial tumours with the high risk
choriocarcinoma regimen (etoposide 100 mg m 2
(E) plus actinomycin D 0.5 mg. both day 1 and 2,
methotrexate 300 mg m-2 day 1 followed by folinic
acid rescue (MTX), alternating weekly with
cyclophosphamide 600 mg m-2 plus vincristine 1
mg m-2 (VCR)) with these results; 2 tumours
producing AFP achieved biochemical PR; 5
tumours producing hCG, 4 biochem CR, 1 early
death. Two patients (1 Ca bladder, hCG; 1 Ca
bronchus, hCG+AFP) were treated with the
relapsed germ cell tumour regimen (E plus cisplatin
100 mg m-2 alternating after 8-10 days with MTX,
VCR and bleomycin 30 mg 48 h infusion). Both
achieved biochem CR. All biochem CR were
accompanied by anatomical PR or CR.
These responses may reflect particular sensitivity
in the marker producing tumours or show that428 JOINT MEETING OF THE BACR & IACR
treatment of common tumours requires
chemotherapy of this intensity. Pts with common
solid tumours should have the serum hCG and
AFP measured so that this approach can be applied
to larger numbers.
The quantitation of the c-myc oncogene product in
testicular and cervical neoplasia
J.V. Watson1, H. Cox', G. Evan1, P. Hendy-Ibbs1,
C. Munn1, J. Stewart1, K. Sikora2
'MRC Clinical Oncology Unit, and 2Ludwig Institute
for Cancer Research, MRC Centre, Hills Road,
Cambridge, UK.
DD9-E7 and other epithelial markers in
adenocarcinomas of the exocrine pancreas
Heyderman', S. Larkin', J. Hermon-Taylor
2 &
A. Grant2
'Department ofHistopathology, UMDS, St. Thomas
Hospital, London SEJ 7RQ, 2Department of
Surgery, St. George's Hospital, London SWJ7 ORE,
UK.
The identification of the primary site of an
adenocarcinoma which presents with metastatic
disease and no localising signs and symptoms is a
major problem in routine surgical histopathology.
In some cases, as with metastatic prostatic or
thyroid carcinoma, markers such as prostatic acid
phosphatase and thyroglobulin, which have a high
degree of specificity, are available for
immunocytochemical staining of fixed tissue
sections. As yet there do not appear to be specific
markers for tumours of the gastrointestinal tract,
which are a common source of metastatic deposits.
While it is often possible to demonstrate primary
lesions in the intestinal tract by barium studies, the
diagnosis of pancreatic adenocarcinoma by a
variety of methods, including CAT-scan, may be
very difficult. Our approach has been to evaluate
an ascites preparation of a mouse monoclonal
antibody, DD9-E7, directed against a pancreatic
tumour line GER, and compare it with monoclonal
antibodies to carcinoembryonic antigen (CEA),
epithelial membrane antigen (EMA) and
cytokeratin (CAM 5.2), using an indirect immuno-
peroxidase technique on 22 primary pancreatic
adenocarcinomas. Some cases were resection
specimens, while others were open pancreatic needle
biopsies. All 22 were positive for DD9-E7, EMA
and CAM 5.2. 20/22 were positive for CEA, but
often weakly and focally, in sharp contrast with
gastric or colorectal carcinomas which are usually
strongly positive. If further work with DD9-E7
supports this high positivity in pancreatic tumours,
its combination with CEA would be useful in
discriminating from tumours from other sites, only
some of which are CEA and/or DD9-E7 positive.
A simultaneous flow cytometric assay for the c-myc
oncoprotein and DNA in nuclei extracted from
archival paraffin wax embedded clinical biopsies is
presented. Nuclei were extracted by pepsin
digestion after dewaxing 20 gm sections. The c-myc
oncoprotein was probed with a mouse monoclonal
antibody, Myc 1-6E10, raised against a synthetic
peptide. The latter corresponded to a hydrophilic
region of the protein predicted from amino acids
171-188 derived from the base sequence of the
cloned gene.
Normal cervical biopsies exhibited raised c-myc
oncoprotein levels as determined by this antibody
when compared with biopsies of cervical cancer.
Carcinoma in situ specimens exhibited two subsets,
one with high and one with low oncoprotein
content. Preliminary results with cervical brushings
from the colposcopy clinic show similar trends.
These findings are potentially significant for mass
cervical screening as up to 500 specimens could be
examined per day with the Cambridge MRC flow
cytometer.
The nuclear DNA and p62C mYc content of 43
primary testicular tumours was analysed. There was
good correlation between the histological
assessment, staining intensity and the levels of
nuclear p62c-mYc obtained. Those with elevated
levels (mean 513 units) of p62C-mYc remained alive
and well at 5 years. Those with low levels (<mean
155 units) died or developed recurrence (P<0.001).
The assay of p62C-myc in testicular tumours may
have prognostic value.
Clinical significance of the c-myc oncogene product
in patients with solid tumours
S.Y.T. Chan, H. Gabra, F. Hill, G. Evan & K.
Sikora
Ludwig Institutefor Cancer Research, MRC Centre,
Hills Road, Cambridge, UK.
We have studied the clinical applications of a set of
monoclonal antibodies raised against synthetic
peptides constructed from sequence data for the
human c-myc oncogene product. One antibody,JOINT MEETING OF THE BACR & IACR 429
mycl-9E10, raised against the c-terminal 32 amino
acids, has been shown to detect the 62,000 dalton c-
myc gene product (p62'-MYc) in colo 320 cells.
Western immunoblotting of sera and urine with this
antibody consistently revealed a single 40,000
dalton band (p40). Quantitative analysis using
dilution dot immunoblotting demonstrated an over
three-fold increase in the titre of p40 in the sera
of patients with a wide range of solid tumours
(n=43), when compared to both healthy controls
(n=20) and patients with non-malignant diseases
(n=25). Peptide mapping by limited proteolytic
analysis of p40 failed to confirm co-identity with
p62C- myc in colo 320 cell lysate. These data suggest
that p40 may be a novel tumour marker.
Radiolabelled antibody was injected i.v. into 14
patients with primary lung cancer and 6 patients
with lung metastases from tumours arising in
different organs. There was selective uptake at the
primary tumour site of 12 patients with carcinoma
of the bronchus suggesting a large quantity of the
p62C-myc in these areas. Metastases derived from
bronchial carcinoma did not take up the antibody.
The patients with pulmonary metastases arising
from sites other than lung also failed to take up
antibody. Successfully localized tumours were all
3 cm or more in diameter. Such antibodies may be
of use in monitoring tumour load and response to
therapy.
Predicting clinical outcome of prostate cancer by
tumour cell DNA content.
M.V.P. Fordhaml, A. Burdge2, J. Mathews', G.
Williams2 & T. Cooke'
Departments of'Surgery, 2 Urology, 3Histopathology,
Charing Cross, and Westminster Medical School,
London W6 8RF, UK.
All patients from 1972 to 1983 with prostate cancer
who underwent prostatectomy prior to treatment
have had tumour cell DNA content measured by
flowcytometry and microdensitometry and this
correlated with clinical outcome. Tissue was
formalin fixed, sectioned and graded histologically
by the Gleason system. A Vickers micro-
densitometer was used to measure tumour cell
DNA content in Feulgen stained 6gm sections,
benign cells acting as controls. Cell suspensions
were prepared from 40pIm sections by pepsin dis-
aggregation and then stained with the fluorochrome
propidium iodide. Fluorescence was measured using
a FACS II flowcytometer for 30,000 cells and the
histogram classified as aneuploid or diploid by
comparison with benign cells.
One hundred and sixty four (90%) of patients
had adequate tissue available and had a known
outcome. Forty five (26.4%) tumours were
aneuploid with an average age at diagnosis of 71.5
+9.5 (range 48-97) and 119 diploid age 71.7+7.3
(range 53-93). At diagnosis, 73% of aneuploid
lesions had local or distant spread compared to
50% of diploid cancers. The average Gleason grade
for aneuploid tumours was 7.0+1.7 (range 4-10)
and diploid 6.1 + 1.9 (range 2-10). Despite any
treatment, survival was worse in the aneuploid
group (X2=21.3, P<0.001) with 75% of the
patients dead at 5 years, 90% from their cancers
compared to 20% of the diploid group.
We conclude that patients with aneuploid
prostate cancers are more likely to have advanced
disease and die earlier from their cancers.
Flow cytometric analysis of the DNA content of
gastric cancer
K.C. Ballantyne, P.D. James, R.A. Robins, R.W.
Baldwin & J.D. Hardcastle
Departments ofSurgery and Histopathology,
University Hospital, Nottingham, and Cancer
Research Campaign Laboratories, Nottingham, UK.
Abnormal tumour cell DNA content (aneuploidy)
is associated with worse prognosis in a variety of
cancers and in a recent Japanese study only 17/54
(32%) gastric cancers were aneuploid.
Seventy-seven consecutive patients, median age
67 years (43-88 years) who underwent gastrectomy
between 1979-1982 were studied. DNA content was
measured by flow cytometry after disaggregating
representative paraffin embedded sections (2 x 30
gm) and staining with diamidinophenylindole
hydrochloride. 48 (62%) had a significant
population of cells (>5%) with an abnormal DNA
content (aneuploid). Two separate tumour blocks
were examined in 24 cases and concordance found
in 19 (79%). No correlation was found between
DNA content of primary tumours and histological
type, histological grade or pathological stage. Data
from 44 patients surviving curative resection were
analysed. 19 (43%) survived over 2 years and 10
remain disease free. The median survival was 23
months (6-67 months) for diploid tumours (n= 16)
and 17 months (4-66 months) for aneuploid
tumours (n= 28).
We conclude that factors other than tumour cell
DNA are responsible for the aggressive nature of
gastric cancer. Only 38% of cancers studied were
diploid compared with 68% of tumours in Japan;
this may reflect a difference in the geographical
pattern of this disease.430 JOINT MEETING OF THE BACR & IACR
Sialic acid levels in peripheral and tumour-draining
blood in carcinoma of the colon
P. O'Byrnel, R. Browne2, A. Johnson2, P. Collins2,
J. Duignan' & D. Bouchier-Hayes'
'Department ofSurgery and 2Department of
Biochemistry, Royal College ofSurgeons in Ireland,
Dublin 2, Eire.
Alterations in the levels of sialic acid in the
peripheral blood of cancer patients have been
reported but its role as a tumour marker is
controversial. In this study, levels of sialic acid were
measured in two blood samples drawn
simultaneously from patients undergoing surgery
for carcinoma of the colon. Peripheral bood (PB)
was taken from the cubital vein and a tumour-
draining blood (TDB) sample was obtained peri-
operatively from a colic vein. 35 patients were
investigated of whom 16 were classified as Duke's
stage A and B and 19 as Duke's stage C and D.
Tumour invasiveness, with involvement of extra
colonic tissue, was assessed at the time of
operation. Sialic acid was measured in serum
samples using an enzymatic coupling procedure
(Boehringer Mannheim Biochemica). The incidence
of raised sialic acid levels was higher in TDB
(68.8%) than in PB (50.0%) in patients at Duke's
stages A and B, but was lower in Duke's stages C
and D patients, 79.0% compared to 84.2%
respectively. When sialic acid in the two blood
samples from individual patients was compared, the
ratio of sialic acid in PB to that of TDB increased
significantly (P<0.05) with cancer stage. The ratio
(PB/TDB) in Duke's A/B patients was 0.92 and in
patients staged as Duke's C/D was 1.16. In patients
with invasive tumours (n=I1) this ratio increased
to 1.40. Thus it would appear that comparing sialic
acid levels in blood from these two sites might
constitute a useful indicator of metastatic tumour
spread and a possible means of assessing the extent
of tumour invasiveness in colon cancer.
Preferential expression of tumour associated antigens
by aneuploid and clonogenic tumour cells
L.G. Durrant', R.A. Robins', N.C. Armitage2, J.
D. Hardcastle2 & R.W. Baldwin1
'Cancer Research Campaign Laboratories,
University ofNottingham, NG7 2RD, and
2Department ofSurgery, Queens Medical Centre,
Nottingham NG7 2UH, UK.
As heterogeneity of antigen expression may prove a
problem in using monoclonal antibody-drug
conjugates in treatment of colorectal tumours,
populations of tumour cells recognised by
monoclonal antibodies have been analysed.
Carcinoembryonic antigen recognised by mono-
clonal antibodies L11/265, C24 and 161 and the
difucosylated blood group H determinant
recognised by monoclonal antibody C14 were both
preferentially expressed in aggressive aneuploid
rather than diploid tumours. Furthermore if the
cells from aneuploid tumours were stained with
monoclonal antibodies C161, C24, C14 or 791T/36
and sorted on a FACS IV, there was an
accumulation of aneuploid cells in the antigen
positive population and a decrease in the antigen
negative population. The enrichment of aneuploid
cells by monoclonal antibody staining and cell
sorting was directly related to both the number of
cells within a tumour which stain and the amount
of staining per tumour cell. Similarly if antigen
positive and negative cells from colorectal tumours
were sorted and analysed for their ability to
incorporate 75Se-selenomethionine in a 24 h growth
assay, the antigen positive cells incorporated 3-6
times more label than the antigen negative cells.
Tumours cells isolated by growth in soft agar
express all three antigens, including p72-791T, an
antigen expressed weakly in the primary tumours.
Despite antigenic heterogeneity in tumours
antibody mediated drug therapy may be useful in
treatment of colorectal cancer as selective
monoclonal antibodies recognise aggressive
aneuploid and rapidly dividing tumour cells.
Cis platinum/chlorambucil in epithelial ovarian
carcinoma
R.J. Atkinson
Department ofOncology, Whitla Medical Building,
Queen's University, Belfast, BT9 7BL, UK.
The annual death rate from ovarian cancer in
England and Wales is in excess of 4,000. This is
greater than the total from cervical and uterine
cancer.
The treatment policy of the joint gynae/oncology
unit at the Belfast City Hospital is debulking
surgery followed by chemotherapy.
From 1980 to 1983, 41 patients were treated with
a combination of cis platinum 20 mg m 2 and
chlorambucil 0.15mgkg-' for 5 days on each of 5
courses. Five years have elapsed since entry of the
first patient. One patient died of myocardial
infarction, leaving 40 evaluable patients. Twenty-
three Stage III/IV patients had disease remaining
after surgery. Of these, eight (34%) had a complete
response, two (8.7%) had a partial response makingJOINT MEETING OF THE BACR & IACR 431
a total response rate of ten (43%). Thirteen (57%)
showed no response.
Currently there are 11 patients alive. The median
survival time of Stage I and II patients is 54+
months while that for Stage III and IV is 21
months (P<0.0114).
A prospective study of alternative response criteria
for bone metastases from breast cancer
R.E. Coleman', G. Mashiter2, K.B. Whitaker',
D.W. Moss3, I.S. Fogelman2, R.D. Rubens'
IICRF Breast Unit and 2Department ofNuclear
Medicine, Guy's Hospital, and 3Department of
Clinical Pathology, Hammersmith Hospital, London,
UK.
Assessment of response in bone metastases is
difficult as radiological evidence of healing may not
be evident for many months. The roles of
biochemical indices of bone metabolism, bone
scanning and symptomatic response were
prospectively studied in 53 patients receiving a total
of 68 treatments. 47 patient treatments are
currently evaluable.
Fifteen patients achieved a partial response (PR)
by UICC criteria, 10 showed no change (NC) for at
least 3 months and 22 had progressive disease (PD).
Bone healing was associated with a transient
increase in osteoblast activity (flare) with a rise at 1
month in alkaline phosphatase bone isoenzyme in
15/15 and osteocalcin in 13/15, followed by a fall in
both towards normal. Eight of the 15 PRs showed
evidence of a flare response on the bone scan,
characterised by increasing activity of base-line
lesions and occasional apparent new lesions at 3
months, followed by improvement at 6 months.
Response in bone was associated with a fall in
urinary calcium excretion (13/15) and symptomatic
improvement (12/15). Symptomatic deterioration,
increasing urinary calcium excretion, hyper-
calcaemia and declining osteoblast activity were
only seen with PD. NC patients usually had
symptomatic and biochemical improvement
particularly when NC persisted for 6 months.
Biochemical and symptomatic assessment of
patients with bone metastases can predict objective
response to systemic therapy.
Metozantrone (M) vs. Adriamycin (A) in
combination chemotherapy for advanced breast
cancer
R.C.F. Leonard', M.A. Cornbleet', S.B. Kaye2,
A.W. Hutcheon', M. Soukop2, S.M. Robinson4 &
J.F. Smyth'
Departments ofOncology, 'Edinburgh, 2Glasgow &
3Aberdeen, UK, and 4Scottish Cancer Trials Office,
Edinburgh, UK.
Having previously demonstrated the activity of M
in patients with advanced breast cancer (Eur J.
Cancer Clin. Oncol., (1984), 20, 1141), we are now
comparing M with A in a multicentre trial, both
drugs being combined with vincristine (V) and
prednisolone (P). To date, 115 patients have been
randomised to receive either VAP (V 1.4mgm-2
ASOmgm-2, P40mgod xSd) or VMP
(V 1.4mgm2, M 14mgm2, P40mgod xSd) each
given q 3/52 x 3, 6, 9 or 12 courses depending on
response. 76 patients are analysed for response to
first line treatment. The trial closes when a
minimum of 100 patients have completed 2
treatment courses. Patients with progressive disease
are eligible for cross-over.
N CR PR NR
VAP 38 5 18 15 Overall response higher for VAP
VMP 38 1 12 25 P=0.02
At all evaluable sites, the response rates reflected
the slightly higher activity of the VAP regimen. The
median response duration to VAP was 8 months
and VMP 5.5 months. However the survival
patterns are identical. Assessed over 3-6 courses,
VMP was clearly less toxic in terms of nausea and
vomiting and especially alopecia. Significant falls in
cardiac ejection (stress) fractions were seen for both
regimens within the recommended accumulated
doses but without clinical toxicity. Thus the more
active and clinically more toxic VAP combination
conveys no survival benefit in patient populations
which were well matched in terms of the usual
prognostic indicators.
Adjuvant chemotherapy with cyclophosphamide,
methotrexate and fluorouracil (CMF) in early breast
cancer: Mechanisms of action
N. Padmanabhan', A. Howell2 & R.D. Rubens'
'ICRF Breast Cancer Unit, Guy's Hospital, London
SE] 9RT, UK, and 2CRC Department ofMedical
Oncology, Christie Hospital, Manchester, M20 9BX,
UK.
Adjuvant CMF in premenopausal patients (pre pts)
with early breast cancer increases relapse free
survival (RFS) and induces permanent ovarian
ablation in 70% by 6 months. The contributions of
ovarian ablation and direct tumoricidal effect of
CMF need to be defined. For this purpose, the432 JOINT MEETING OF THE BACR & IACR
relation between estrogen (ER) and progesterone
(PR) receptor status, RFS and CMF was studied in
407 pts, pre: 107 and 100, controls and CMF
respectively, and postmenopausals (post): 101 and
99, entered into a randomized adjuvant CMF trial.
Median follow up 36 and 40.5 months, pre and post
respectively. Results: In pre ER but not PR, was
strongly associated with a longer RFS in controls
while for pts on CMF PR was strongly and ER less
strongly associated with a longer RFS. In post there
was no association between ER, PR, CMF and
RFS. On analyses of subgroups of pre longer RFS
and survival with CMF compared to controls was
confined to PR+ and ER+ PR+ subgroups.
There was no difference in RFS between controls
and CMF for ER- PR- subgroup of pre and in
all post subgroups. Conclusion: The alteration of
the relation between receptor status and RFS in pre
by CMF, longer RFS with CMF being confined to
pre with PR+ tumours, no prolongation of RFS in
ER- PR- pre (pts in this subgroup unlikely to
respond to ovarian ablation) and in post (CMF has
no intrinsic hormone activity and does not change
the levels of steroids and gonadotrophins) given
CMF, suggest that much of the effect of adjuvant
CMF in pre is due to ovarian ablation.
High dose carboplatin and autologous bone marrow
infusion
C.J. Gallagher, M. Gore, I.E. Smith, S.J. Harland
& E. Wiltshaw
Department ofMedicine, Royal Marsden Hospital,
London SW3, and Sutton, Surrey, UK.
Carboplatin (JM8) has proved to be as effective as
cisplatinum in ovarian cancer and to be active in
small cell lung cancer. The dose limiting toxicity
has been myelotoxicity without the neuro- or
nephro-toxicity associated with cisplatinum. We
have therefore investigated the use of increasing
doses of JM8 with autologous bone marrow
infusion (ABMI) in a selected group of poor
prognosis patients with ovarian or small cell lung
cancer. In half the patients receiving 650 mg m-2
or more, bone marrow harvested under general
anaesthetic and 2 x 108 nucleated cells kg- 1
returned 16h after treatment or cryopreserved and
returned after subsequent courses.
Myelotoxicity was unaffected by the use of
autologous bone marrow infusion following JM8 at
650 mg m-2 and 800 mg m2. Up to 5 courses per
patient have been given at 650 mg m-2 without
ABMI but so far no patients have received more
than two courses at 800 mg m-2. There has been
no clinical neurotoxicity, but two patients have
shown a fall in glomerular filtration rate.
Dose
mgm-2 Patients Courses
520 5
650 6
800 6
1000 1
17
15
10
I
With
ABMI Myelotoxicity
0
5
5
WBC
2.4-4.4
2.4-7.6
0.4-3.2
0.8
Platelets
42-220
63-394
9-47
19
Alpha lymphoblastoid interferon for non-invasive
bladder cancer
R.T.D. Oliver123, J.H. Waxman123, H. Kwok3,
C.G. Fowler2, P. Mathewman3 & J.P. Blandy2,3
lThe London Hospital, 2St. Bartholomew's Hospital,
and 3The Institute of Urology, London, UK.
Sixteen patients with recurrent bladder cancer (8
with multiple papillary recurrences and 8 with flat-
in-situ disease) were treated with topical alpha
lymphoblastoid interferon. Each patient received 8,
once-weekly intravesical instillations of 50 mega
units of interferon. Response was assessed at formal
cystoscopy one to three months from the
completion of treatment and a comparison made
with previous patterns of recurrence. Three of the 8
patients with papillary tumours had no recurrences,
and a further three an apparent reduction in the
rate of tumour recurrence with less than 50% of
expected tumour present. No patient with flat-in-
situ carcinoma responded. Although the response to
interferon was less than that with conventional
intravesical chemotherapy, these results suggest that
further investigation of topical interferon is
warranted.
A comparison of intranasal and depot preparations of
buserelin in the management of advanced prostatic
cancer.
J.H. Waxman' 2'3', J. Sandow4, A. Man',
M.J. Barnett', & R.T.D. Oliver1 2,3
1St. Bartholomew's, 2The London Hospital,
3Institute of Urology, London, and 4Hoechst
Pharmaceuticals, Switzerland
Buserelin (D-Ser (TBU) 6 LHRH Ethylamide), a
long-acting analogue of gonadotrophin releasing
hormone, has been previously applied to prostatic
cancer as thrice or five times daily, intranasal, orJOINT MEETING OF THE BACR & IACR 433
daily subcutaneous regimens. Elderly patients may
have obvious difficulties in complying with such
treatment programmes. A monthly depot
preparation of Buserelin, which releases the
analogue at a mean daily rate of 150pg was used to
treat 12 men with advanced prostatic cancer. The
hormonal effects of depot Buserelin were compared
with that of 200pg of Buserelin given five times
daily as an intranasal preparation to 17 patients.
Both regimens resulted in suppression of serum
testosterone into the castrate range (less than
2.5nmol -1) at the end of the fourth treatment
week (mean serum testosterone intranasal regimen:
2.3 nmol I-1, depot regimen: 2.0 nmol I-1).
Reimplantation was not followed by any
significant increase in serum testosterone concen-
trations, indicating effective gonadal suppression.
(Mean serum testosterone pre=2.0nmolI1 and a
4h post re-implantation = 1.9nmol1-1). It is
concluded that monthly depot Buserelin offers an
effective alternative to intranasal therapy.
Metoclopramide (M) and dexamethasone (D) anti-
emesis-high dose metoclopramide (HDM) continuous
(C) vs. intermittent infusion (I)
P. Warrington, S. Allan, E. Bayliss, D. Farquhar,
M. Cornbleet, J. Macpherson, J. Smyth, & R.
Leonard
Department Clinical Oncology, Western General
Hospital, Edinburgh, UK.
HDM is an effective anti-emetic against cis-
platinum (P)-induced emesis and its efficacy is
increased in combination with D. HDM is usually
administered by I which results in drug peaks,
troughs and accumulation. Control of emesis has
been reported to require a plasma concentration of
85jugml- . We have compared the blood levels
achieved by I and C and correlated these with anti-
emetic efficacy. The incidence of side effects was
also compared. 28 patients receiving P com-
binations were randomised to receive either IM+1D
or CM +D and received the alternate regimen on
subsequent treatment. IM regimen comprised M
7mgkg-1 in 500 ml 0.9% sodium chloride
administered in 100ml aliquots 15min before P and
thereafter 2 hourly x 4. CM regimen comprised a
3mgkg-1 loading dose of M 15min before P then
continuous infusion of 4mgkg-1 for 8h. D 20mg
was given by a 15min infusion 30min before P.
Nausea, retching, vomiting, diarrhoea and adverse
reactions were recorded on a standard
questionnaire. CM regimen gave a significant
reduction in mean nausea (CM =16% IM =35%
P<0.001, visual analogue
reduction in vomiting (_3
IM = 12, P<0.05) significant
incidence of diarrhoea (P<0.05).
scale) significant
episodes CM =4
reduction in the
Meanplasmalevelsofmetoclopramidein 14patients(pgml-1)
Time (h) IM trough IMpeak
0
2
4
5
CM
- 0.62+0.25 1.47+0.56
0.98+0.16
0.21+0.60 0.82+0.18 0.89+0.18
0.44+0.16 1.03+0.25
0.93+0.31
6 0.52+0.17 1.21 +0.26
8 0.75+0.25 1.34+0.34 0.99+0.35
The mean CM blood levels did not fall below 0.85
pgml-1 whereas the IM regimen resulted in M
levels below 0.85 pgml-' during the first 4 h. The
CM gives a better anti-emetic control with fewer
side effects compared with IM.
Advanced squamous carcinoma of the lung. Trials of
etoposide vs no treatment and etoposide vs etoposide
+cyclophosphamide
G. Anderson1 & E. Peel2
Lung Cancer Treatment Group. 'Newport Chest
Clinic, Newport, NP9 4GA. and 2 Wallsend Chest
Clinic, Tyne and Wear, NE28 7PE, UK.
There is no evidence that chemotherapy prolongs
life in advanced squamous carcinoma of the lung.
Most trials have concentrated on the remission
incidence with few studies of the effect of treatment
on survival.
In two co-operative studies centres entered
patients either into randomised trials of no
treatment versus oral etoposide 300 mg m-2 (O vs
1) or the same dose of etoposide vs the same dose
of etoposide+cyclophosphamide 300 mg m-2 i.v.
(1 vs 2). Patients had biopsy proven squamous
carcinoma considered too advanced for radical
radiotherapy or for surgery. Palliative radiotherapy
could be given up to a dose of 3,000 cGy. Patients
receiving active treatment received 6 Cycles of
chemotherapy.
In the comparison of 0 vs 1 for the whole group
there was no significant benefit of treatment
(P=0.37 on log rank analysis median survival on
treatment or no treatment 194 days). In 39 patients
with M1 disease there was a significant
improvement in survival (P=0.045 median survival
no treatment 103 days, etoposide 251 days). There434 JOINT MEETING OF THE BACR & IACR
was no significant benefit of treatment for patients
with MO disease. It is surprising that benefit
emerged to the M, group.
In the study of 1 vs 2 there was no survival
advantage for the whole group (P=0.37 median
survival, 1 drug 178 days, 2 drugs 193 days).
Separate analysis of MO and M, group also showed
no significant survival advantage.
A comparative study of two methods of treating
oesophageal cancer related to prognosis
C.T. Doyle', M.M. Cole2 & D.G. Barry2
'Department ofPathology and 2Department of
Statistics, University College, Cork, Eire.
One hundred and forty eight patients with
squamous cell carcinoma of the oesophagus were
retrospectively divided into two groups of 32 men
and 42 women. One group had been treated
palliatively by intubation, the other surgically by
oesophagectomy. Age, sex, duration of symptoms,
location of the cancer, differentiation and survival
time from diagnosis were coded for both groups,
and extent and type of invasion, local tissue
reaction, and any associated mucosal premalignant
lesions for the oesophagectomy group.
Survival data were analysed using the propor-
tional hazards regression model and the PIL and
P2L programmes of the BMDP statistical software
package.
The best prognosis was found among women,
under 60, treated by oesophagectomy, who had well
differentiated cancers in the lower third of the
oesophagus, with no premalignant lesions in the
adjacent mucosa. Patients with the worst prognosis
were also treated by oesophagectomy and had
moderately differentiated cancers in the upper and
middle thirds. The results allow identification of
four prognostic groupings - 'Good', 'Fair', 'Poor'
and 'Bad' which in future should assist the decision
between palliation and oesophagectomy.
High-grade non-Hodgkin's lymphomas: Long term
results of treatment with combination chemotherapy
D. Cunningham', A. Hepplestone2, N.L. Gilchrist',
J.H. Dagg2, I.L. Evans3 & M. Soukop'
'Department ofMedical Oncology, Royal Infirmary,
Glasgow G4 OSF, Departments of2Medicine and
3Haematology, Western Infirmary, Glasgow Gil
6NT, UK.
High-grade non-Hodgkin's lymphomas are a
heterogenous group of tumours which have a poor
prognosis unless treated with chemotherapy. Using
regimens such as MOPP and BACOP long term
survival has been reported in up to 40% of patients
which has led to a reluctance of clinicians to use
more intensive chemotherapy regimens which offer
the prospect of improved survival, and ultimately
cure.
Between 1975 and 1982 in 2 centres in Glasgow,
53 previously untreated patients with high grade
non-Hodgkin's lymphomas received chemotherapy
consisting of one of the following regimens - CVP,
MOPP, CHOP or BACOP. Twenty nine patients
(55%) entered complete remission (CR), 20 (38%)
had partial remission (PR) and 4 (7%) had
progressive disease (PD). Of the 29 patients CR; 9
have relapsed and died, 5 died of infection, 4 died
of non-malignant causes and 11 (21%) remain alive
and disease free. The median survival for the CR
group is 40 months. All of the patients in the PR
and PD groups are dead, median survival 11
months.
These chemotherapy regimens will cure only the
minority of patients with aggressive lymphomas and
the use of more intensive regimens in the
management of this disease is indicated.
Weekly outpatient chemotherapy (EMOP/CA) for
non-Hodgkin's lymphoma and relapsed Hodgkin's
disease
J.A. Ledermann, D. Pektasides, L. Holden, G.J.S.
Rustin & E.S. Newlands
CRC Department Medical Oncology, Charing Cross
Hospital, London W6 8RF, UK.
We have given an intensive 7 drug combination,
weekly, on an out-patient basis for 3 months to 14
previously untreated patients (pts.) with 'high-
grade' NHL, 17 pts. with relapsed NHL (12 'high-
gd.' 5 'low-gd.') and 6 with relapsed Hodgkin's
disease (HD). EMOP/CA comprises etoposide
200mgm 2, methotrexate 50mgm 2, vincristine
1.4mgm-2 (max. 2.0mg) i.v. alternating each
week with cyclophosphamide 400mgm-2 and
adriamycin 20 mg m-2 i.v. Prednisolone 100mg
was given on alternate days, to reduce the steroid
toxicity, throughout the 12 weeks of treatment.
In the 'high-gd.' NHL group 7 out of 13
evaluable pts. achieved CR (54%) and 4/13 (31%)
PR. 2 early deaths occurred due to infection (WHO
perf. gd. 3) 5/13 had additional RT. On follow-up
7/14 (50%) pts. remain without evidence of disease
at 5-16 months (median 13 mo.) 1 pt. relapsed at
7 months. In relapsed NHL 'high-gd.' 7 (58%)
achieved a further CR of 1-6 mo. (med 5 mo.),JOINT MEETING OF THE BACR & IACR 435
2 PR, 1 NC. Responses were seen in all those with
'low-gd.' histology, 2 CR, 3 PR. In HD 2/6 had a
CR and 4/6 PR.
The toxicity has been acceptable with occasional
modifications in the dose of steroids and inclusion
of folinic acid rescue in those with mucositis. I.v.
antibiotics for infection were rarely required. This
intensive weekly regimen has produced encouraging
results; the schedule is similar to MACOP-B of
Klimo and Connors (Ann. Int. Med. (1985), 102,
596) who treated 61 patients but the toxicity is less.
Cutaneous malignant melanoma tumour type in
Northern Ireland: Possible aetiological implications
L.G. Gordon & W.S. Lowry
The Queen's University, Belfast BT9 7BL, UK.
The evaluation of all cases of malignant melanoma
in Northern Ireland over a 5 year period encom-
passes a total of 240 cases of cutaneous malignant
melanoma (CMM). The distribution of tumour
types in this study reveals that 42% are nodular
lesions (NM), and 27% are superficial spreading
melanoma (SSM); 20% are lentigo malignant
melanoma (LMM), and 11% are acral lentiginous
melanoma (ALM). This is one of the highest
percentages of LMM so far reported.
All tumour types have a majority of lesions
greater than 1.5 mm in thickness. Even LMM has
70% of lesions thicker than 1.5 mm. Nodular and
ALM lesions are most ulcerated. Anatomical site
distribution shows significant differences between
types. ALM is most common on the foot (40%).
LMM, not surprisingly, is most common on the
head and neck (86%). SSM is most common on the
leg (43%). NM reveals its highest incidence on the
leg (39%) and head and neck (23%). The excess
incidence in females in Northmrn Ireland was
evident for all tumour types.
Each of the four types has a statistically different
age curve, which together with the variation in site
distribution supports a distinctive aetiology for
each type. LMM, with highest incidence in the over
65 age groups, follows the age pattern expected
with a dose dependent relationship. ALM are most
common between the ages of 50 and 70. SSM
increases dramatically between the 20-29 age group
and the 30-39 group, and then levels out. The age
distribution of NM is consistent with the suggestion
that many nodular melanomas are actually
advanced lesions of SSM and LMM. Studying each
tumour type independently helps form a clearer
picture of melanoma aetiology from epidemio-
logical evidence.
Improved curability of teratoma in the West of
Scotland - a review of 152 cases
J.D. Graham, S.B. Kayne, D.J. Kerr, L. Mill, &
K.C. Calman
Department ofMedical Oncology, Gartnavel General
Hospital, Glasgow, UK.
Between January 1981 and July 1985, 104 patients
with testicular teratoma were referred, mainly from
urologists in the West of Scotland. Twenty-five had
Stage I disease (24%). The remainder received
chemotherapy and the volume of metastatic disease
has been graded using the system recently proposed
by the MRC working party (1985, Lancet i: 8). By
prognostic staging these were as follows: Small
volume metastases (SVM) 44 (42%); large volume
(LVM) 20 (19%); very large volume (VLVM) 15
(14%). All patients with metastatic disease were
treated with platinum containing regimes according
to EORTC urology group protocols. A total of 8
patients died: 1/44 with SVM, 0/20 with LVM and
7/15 with VLVM. Thus, 71 out of 79 patients (90%)
presenting with metastatic disease are alive, 69 of
whom have been off treatment for 3-53 months.
During the same period 6 out of 8 patients treated
for extragonadal teratoma died.
In contrast 13 out of 35 patients treated for
testicular teratoma between 1975 and 1980 died. By
Stage these were as follows: Stage I 10 (28%); SVM
10 (28%), 2 dead; LVM 6 (17%), 3 dead; VLVM 9
(25%), 6 dead. There were five patients treated for
extragonadal teratoma with 4 deaths.
These data show that an increasing proportion of
patients now present with a smaller metastatic load
and that virtually all can be cured. The small
number of patients presenting with VLVM and
extragonadal disease continue to have a poor
prognosis indicating a need for alternative chemo-
therapy schedules for this subgroup.
Sister chromatid exchange frequency in the
lymphocytes of patients with lymphomas having first-
line chemotherapy
T. Brown1, A.A. Dawson2, B. Bennett2 & J.L.
Watt'
'Department ofGenetics, 2Department ofMedicine,
University ofAberdeen, Aberdeen Royal Infirmary,
Foresterhill, Aberdeen, AB9 2ZB, UK.
We have already demonstrated dramatic changes in
the sister chromatid exchange (SCE) frequency in
the peripheral lymphocytes of patients having
MVPP therapy for Hodgkin's disease; the elevation436 JOINT MEETING OF THE BACR & IACR
rising rapidly but falling before the end of the
course. With CHOP therapy used in treating high-
grade non-Hodgkin's lymphoma, a comparatively
minor rise was demonstrated in the samples taken
immediately before each pulse of therapy.
When samples were analysed in the first day after
intravenous therapy however, a pattern of steep rise
at 2h, and fall at 24h was seen with MVPP therapy,
whereas CHOP therapy produced a far greater rise
at 2h, and increasing still further at 24h.
The findings are of potentially great significance,
especially with respect to therapy-induced malig-
nancy.
A study of the problems that cancer poses for the
patient and the family
M. Casey, R. Conroy, L. Daly, J. Fennelly, P.
Herity, N. Hilliard, M. McCambridge & M.
Moriarty
St. Luke's Hospital, Cancer Research Unit, Rathgar,
Dublin 6, Eire.
A study of 200 cancer patients and the problems
that cancer poses for them was carried out in St.
Luke's and St. Vincent's Hospital between May
1983 and May 1984; one responsible relative for
each patient was also included in the study.
The main areas of concern were communication
with health professionals, physical and psycho-
logical symptoms and their management, social
dependency, care in hospital and at home, and
financial and social aspects of the illness.
In the four weeks prior to the interview the
patients had distress from
Symptom %+ % Gained % No reliefor
Relief did not seek it
Lassitude
Insomnia
Pain
65.5 16.0
53.0 64.0
52.0 64.0
84.0
36.0
36.0
There was a significant relationship also to anxiety
and depression.
Coping with cancer: A randomised study of
relaxation training (ReT) in patient care and
management
S. Bindemann, S.B. Kaye, J. Welsh, T. Habeshaw
& K. C. Calman
Department of Clinical Oncology, University of
Glasgow, 1 Horselethill Road, Glasgow GJ2, UK.
A randomised trial of Relaxation Training (ReT)
was carried out with the purpose of evaluating this
form of psychologic support for cancer patients.
Seventy one new patient-referals (32 males 39
females) completed the study. Measurement of
effect was achieved by means of a 'battery' of
questionnaires. These included, the Leeds Self-
Assessment of Anxiety (LSA) and of Depression
(LSD) Scale, the Stait-Trait Anxiety Inventory
(STAI), the General Health Questionnaire (GHQ-
60) - a psychiatric disorders screening test and
the Actual/Ideal-Self Perception Questionnaire.
(Bindemann et al 1984, Br. J. Cancer, 49: 387.) A
structured interview schedule was developed for use
in the study. Baseline data were gathered at
recruitment and evaluation of ReT took place at 6
and 12 weeks. Raised anxiety scores of male
control Ss - compared to scores reported for male
experimental subjects - were noted at both 6 and
12 weeks. (P= <0.01) Greater confidence levels
emerged in similar differences between female
groups (P= <0.001). Male group depression scores
were statistically comparable throughout the life of
the study. However, depression scores for female
control Ss were higher at 6 and 12 weeks
(P= <0.01 and P= <0.001). Elevated GHQ scores
were reported for male control Ss at 12 weeks only
(P= <0.05). Similar differences, but in this instance
at both 6 and 12 weeks, distinguished the two
female groups (P= <0.05). Groups' placement on
the factor of intrapsychic functioning ascribes a
lower level of psychic well-being to male control Ss
at 6 and 12 weeks (P= <0.05). Differences on this
variable were again most apparent between female
control Ss (lower) and female experimental Ss
(higher) at 6 and at 12 weeks (P= <0.02,
P= <0.002). Quality of life, as measured by
specific references to actual- and ideal-self
perception, was more adversely affected among
control subjects of both sexes. Data obtained by
clinical interview, undertaken by members of
medical staff within the Department, concur fully
with results summarized above. In conclusion, we
suggest that these results ascribe value to ReT as a
useful means of supporting cancer patients,
particularly female patients, in their need to
mobilize and maximize upon actual coping
resources.
Familial medullary thyroid cancer - screening the
family of the apparently sporadic case
B.A.J. Ponder
(for the CRC Medullary Thyroid Group)
Institute ofCancer Research, Sutton, Surrey, SM2
5PX, UK.
Medullary Thyroid Cancer (MTC) occurs inJOINT MEETING OF THE BACR & IACR 437
sporadic and familial (autosomal dominant) form.
About 10% of new cases of MTC are recognisable
as familial on history: the other 90% are
categorised as 'apparently sporadic'.
The value of early diagnosis by calcitonin
measurement in families at risk is well established.
Few families of patients with apparently sporadic
MTC are offered screening, however, probably
because it is believed that onset in middle age or
later and lack of immediate family history exclude
the familial form with high probability.
Analysis of data from 42 known MTC families
and 37 consecutively screened 'apparently sporadic'
families in the CRC group register showed (1) that
a minimum of 15% of consecutive unselected
(sporadic' families screened were in fact familial,
(2) that of a total 12 'sporadic' cases found by
screening to be familial 6 were initially diagnosed
aged >40 years, and (3) that 30% of obligatory
gene carriers in known families will still not be
diagnosed clinically by age 70. Potentially, 2/3 of
new families with MTC will be discovered by
screening, and only 1/3 by family history.
Advanced age at diagnosis in the index case, and
lack of history even in elderly parents, are not
sufficient to rule out familial involvement.
We conclude that screening should be considered
for the family of every new case of MTC.
Categorisation of 'apparently sporadic' families as
high- or low-risk may in future be possible using
the family structure combined with age at onset
data derived from the register.
Augmentation of human NK cell activity by cloned
NS1 influenza viral gene products
R.C. Rees', B.J. Dalton2, & J.F. Young3
'Department of Virology, University ofSheffield
Medical School, UK, 2Departments ofImmunology
and Anti-infectives Therapy and 3Molecular
Genetics, Smith, Kline and French Laboratories,
Philadelphia, USA.
E. coli cloned influenza viral gene products were
assessed for their ability to augment human natural
cytotoxicity in overnight cultures (18 h) at 37°C.
Nylon wool non-adherent PBMC were activated by
a number of viral gene proteins, the most effective
being the NSI protein (but not NS2 protein) and
haemagglutinin and matrix antigen components
fused to the N-terminal 81 amino acid sequence of
NSI. Interferon (IFN) was detected in cultures
where enhanced cytotoxicity was evident and identi-
fied as both IFNa (>90%) and IFNy (<10%).
The cell type responsive to antigen stimulation was
present in Percol fractions enriched for LGLs, and
NSI activated PBMC were shown to localise in the
low density Percol fractions (LGL enriched). Using
specific anti-IFN-antisera it was determined that
IFNox, but not IFNy, was responsible for enhancing
cytotoxicity. Interferon induction and activation of
cytotoxicity could not be ascribed to the presence
of contaminated bacterial products. These studies
suggest that NSI protein and constructs containing
a portion of the NSI antigen augment human
NK cells via the induction of IFN.
Tissue-type plasminogen activator: correlation with
oestradiol receptors in human breast carcinomas
M.J. Duffy, P. O'Grady & H.R. Lijnen
St. Vincent's Hospital, Dublin, Eire and University
ofLouvain, Belgium.
Plasminogen activator (PA) is a protease which
catalyses the conversion of the inactive plasminogen
to the active plasmin. In most tissue it exists as 2
main forms, i.e. tissue-type PA (t-PA) and
urokinase-type PA (UK-PA). Since PA is induced
by oestradiol in both rat uteri and human breast
cancer cells in culture, its presence in human breast
cancer biopies is a potential marker for a functional
oestradiol receptor (OER). The purpose of this
investigation was therefore to see if any correlation
existed between OER and either total PA, or its
different forms in human breast tumours.
t-PA as measured by an immunoradiometric
assay was found in 1/31 (3.2%) of tumours without
OER, in 4/13 (31%) of tumours with borderline
level of OER and in 49/94 (52%) of tumours with
OER (P<0.001 for ER-negative versus ER-positive
group). In contrast to t-PA, neither UK-PA activity
nor total PA activity showed any significant
relationship with OER. Other oestrogen-inducible
proteins such as peroxidase and creatine kinase also
showed no significant correlation with OER.
Our results show that t-PA antigen is mostly
confined to OER-containing carcinomas. Tumours
possessing OER and t-PA may contain a functional
receptor while those containing OER but lacking t-
PA may have an inactive receptor. If so OER-
positive, t-PA positive tumours would be expected
to respond to hormonal therapy while OER-
positive, t-PA-negative carcinomas would not. This
hypothesis is currently being tested.438 JOINT MEETING OF THE BACR & IACR
Increased levels of tissue plasminogen activator
mRNA during progressive transformation of
ethylnitrosourea-induced rat brain cells
L.J. Green, P.C. Rumsby and J.P. Roscoe
Department ofCell Pathology, School ofPathology,
Middlesex Hospital Medical School, Riding House
Street, London WIP 7LD, UK.
A system for investigating changes in the
progressive transformation of rat brain cells has
been developed using ethylnitrosourea (ENU) as
the inducing carcinogen (Roscoe & Claisse, (1976),
Nature, 262, 314). A series of cultures derived at
different times after in vivo exposure to this
carcinogen as well as cultures from tumours and
control animals has allowed the identification of
stages during transformation. Differences in
plasminogen activator (PA) activity have proved to
be of particular interest in this transformation
system (Roscoe et al., (1980), Br. J. Cancer, 42,
756).
Using a fibrin-agarose overlay assay a higher
level of PA activity has been found in the tumour
cultures than in control cultures derived from adult
rat brain. Northern blot analysis of mRNA
demonstrated a higher level of tissue-type
plasminogen activator (t-PA) mRNA in rat glioma
than in normal rat brain cultures. Cultures derived
2 days after exposure to ENU had low PA activity
at early passages. On further passaging, there was
an increase in PA activity which preceded the
ability of cells to grow in soft agar or syngeneic
animals. The tPA mRNA level in these cells was
also low initially and increased on passaging,
correlating with the rise in enzyme activity found
during the progression of the cells to the fully
transformed phenotype. Control cultures (buffer
exposed) had no measurable PA activity of tPA
mRNA even after comparable passaging. The
results open the way to investigations at a
molecular level of alterations in the control of a
specific proteolytic enzyme early in transformation.
Glycoprotein expression in normal keratinocytes and
squamous carcinoma cell lines
Z. Rayter' & R.A.J. Mcllhinney2
'Ludwig Institutefor Cancer Research, The Haddow
Laboratories, Royal Marsden Hospital, Clifton
Avenue, Belmont, Sutton, Surrey, SM2 SPX, 2MRC
Unit ofAnatomical Neuropharmacology, University
Department ofPharmacology, South Parks Road,
Oxford, UK.
Glycoprotein expression in normal keratinocytes
has been compared with that in the squamous
carcinoma cell lines LICR-HN2, -HN5, -HN6 and
on SV40 transformed keratinocyte cell line. Two-
dimensional gel electrophoresis has been employed
to separate detergent-extracted glycoproteins which
have then been identified using a 12'I-Con A
overlay. A consistent 3 to 4-fold increase in
expression of a 35 Kd protein with an iso-electric
point of 5 has been observed in the squamous
carcinoma cell lines compared to normal
keratinocytes. The expression of this protein is
decreased in quiescent cells compared with
exponentially growing cells. This protein has a
similar molecular weight and iso-electric point to
that of cyclin or proliferating cell nuclear antigen
(PCNA). However, it is affected by mild
trypsinization and therefore appears to be on the
cell surface.
Cyclin was immunoprecipitated from HN-6 cells
labelled with 35S methionine, and overlay with 1251.
Con A on a two-dimensional gel failed to show any
binding. Our conclusion is that we have identified a
glycoprotein whose expression is increased in all the
squamous carcinoma cell lines, and is not cyclin,
the expression of which may be related to cell
growth.
The effect of prolonged tamoxifen treatment on
expression of oestrogen receptor by ZR-75-1 human
breast cancer cells
H.W. Van den Berg', M. Lynch', R. Clarke2 & J.
Nelson2
Departments of ITherapeutics and Pharmacology
and 2Biochemistry, Queen's University ofBelfast,
UK.
Continuous tamoxifen, (Tam), therapy is of proven
value in prolonging disease free interval in breast
cancer patients. The effects of such treatment on
surviving tumour cells, or the consequences of
cessation of therapy are largely unknown. We have
maintained ZR-75-1 human breast cells in growth
medium containing tamoxifen, (1-2 MM), for 6
months. Cells, designated ZR-TAM, grow slowly in
the presence of the antioestrogen, requiring
subculturing every 2-3 weeks. Determination of
oestrogen receptor, (ER), content 5 days after
transfer to drug free medium was achieved using a
whole cell binding assay. Using free 3H-oestradiol
concns. ranging 0.3 to 3.6 nM a single class of ER
receptor was detectable in ZR-75-1 cells, (Bmax 225
+ 19 (s.e.) fmol mg-' protein, Kd 0.57 + 0.11
nM). Expression of this high affinity receptor was
markedly reduced in ZR-TAM cells, (Bmax 56 +JOINT MEETING OF THE BACR & IACR 439
12 fmol mg'- protein, Kd 0.21 + 0.08 nM). Woolf
or Scatchard analysis of binding data also revealed
the presence of low affinity binding sites in ZR-
TAM cells. Preliminary data have demonstrated
saturability of these sites at high free ligand
concentrations with binding characteristics similar
to those of previously described nuclear type 2 sites,
(Kd - 10-8M). In contrast to the results of earlier
experiments, ZR-TAM cells grew at the same rate
as ZR-75-1 cells in absence of Tam and cell
proliferation was inhibited to the same extent on re-
exposure to Tam. We conclude that human breast
cancer cells can withstand prolonged exposure to
Tam without resistance occurring, although the
expression of high affinity ER is greatly reduced.
We are currently investigating the possible role of
the low affinity ER binding sites in mediating the
effects of Tam.
Cytotoxic drugs induce a reduction in the 17p
oestradiol (E2) binding capacity of MCF-7 human
breast cancer cells which is accompanied by a
reduction in the rate of DNA synthesis
R. Clarke', J. Morwood', J. Nelson', H.W. van
den Berg2 and R.F. Murphy'
Departments of'Biochemistry and 2Therapeutics,
The Queen's University ofBelfast, N. Ireland, UK.
MCF-7 cells were exposed to clinically achievable
concentrations of adriamycin (ADR), melphalan
(MEL) and 5-fluorouracil (5-FU) for 24 h prior to
estimating the oestrogen receptor (ER) levels using
a whole cell binding assay.
ADR, MEL and 5-FU reduced the ER content
of MCF-7 cells in a dose dependent manner, but
the affinity of remaining ER for the ligand, the
uptake of the ligand by the cells, and the rates of
protein synthesis and cell proliferation were not
significantly different from untreated cells. A
reduction in the E2 binding capacity of the cell
population was accompaneid by a reduction in the
rate of newly synthesised DNA.
These results suggest that the reduction in ER
levels is not the result of reduced synthesis of new
ER protein. The ER is currently thought to be
predominately located in the nucleus where it
becomes more tightly associated on binding E2
(Molinari et al, (1985), Biochem. Biophys. Res.
Comm., 128, 634). Previously bound E2 may not be
available to exchange with radiolabelled E2.
Therefore, the only ER accessible for binding may
be that associated with newly synthesised DNA.
Alternatively, the cytotoxic drugs may be
influencing the rate of ER recycling.
These observation may have important
implications for ER determination in patients
previously treated with cytotoxic drugs as well as
for combined regimes using cytotoxic drugs and
antioestrogen therapy.
Conditioning factors affecting growth of human skin
keratinocytes
S. McDonnell and M. Clynes
School ofBiological Sciences, National Institutefor
Higher Education, Glasnevin, Dublin 9, Eire.
Irradiated (or mitomycin C-treated) 3T3 feeder
layers are generally required for primary culture of
disaggregated human skin keratinocytes (HSK),
even when subsequent subcultures can be achieved
without feeders (Peehl & Ham, (1980), In Vitro, 16,
516). In serum-free optimized media normal HSK
show density-dependent effects (Tsao et al., (1982),
J. Cell Physiol, 110, 219) and we have observed a
low-density cut-off point in SCC-9, a line derived
from squamous cell carcinoma of the tongue
(Rheinwald & Beckett, (1982), Cancer Res., 41,
1657). These 3T3 and SCC-9 feeder effects are
mediated at least in part by diffusible factors; we
have found, using SCC-9 as an indicator line, that
both 3T3 and SCC-9 can act as feeders in a double-
layer agar assay, and that conditioned media (CM)
from both lines increases plating efficiency and
colony size in monolayer assay. SCC-9 CM is also
active in the transforming growth factor (TGF)
assay, using NRK as the indicator line, and this
activity is associated with material of >5,000 mol.
wt. The 3T3 and SCC-9 products described here
may be useful in improving growth conditions for
normal and malignant HSK, and may possibly have
relevance to in vivo control of epithelial cell
proliferation.
In vivo susceptibility of dormant carcinoma cells to
alkylating agents
P.V. Senior & P. Alexander
CRC Medical Oncology Unit, Southampton General
Hospital, Southampton S09 4XY, UK.
We have established a transplantable mammary
carcinoma syngeneic in the hooded Lister rat which
will only grow in rats bearing a subcutaneously
implanted pellet of oestrogen. In the absence of
exogenous oestrogen transplanted carcinoma cells
remain dormant, but when the rats receive an
oestrogen pellet growth commences at a rate440 JOINT MEETING OF THE BACR & IACR
comparable to that of transplants made into rats
already receiving oestrogen. Carcinoma cells were
either inoculated s.c., when they gave rise to locally
growing tumours, or into the arterial circulation,
via a cannula introduced into the left ventricle,
when metastases grew predominantly in the
adrenals, ovaries, bone and lung. The response of
dormant and actively dividing carcinoma cells to
alkylating agents was compared by administering
the alkylating agents either before or after implan-
tation of the oestrogen pellet. Cyclophosphamide in
the dose range of 40-180 mg kg 1 given during the
dormant phase caused no delay in growth which
occurs after oestrogen had been given for the s.c.
tumour and only produced a marginal effect on the
metastases. Cyclophosphamide was, however,
highly effective in delaying both local and
metastatic tumour growth when given after
oestrogenisation (i.e. when the carcinoma cells were
actively growing). On the other hand, BCNU at 7
mg kg-1 was highly effective against this
carcinoma, both in the the dormant state and in the
actively growing phase. These findings may be
relevant to the design of protocols of adjuvant
chemotherapy since dormancy may contribute to
the resistance of some micro-metastases.
Characterisation of vesicles shed from Landschutz
ascites tumour in association with malignancy-related
fucopeptides
M. McGuinness', E. Walsh2 & H. Smyth'
'Department ofBiochemistry, University College,
Dublin 4, 2School ofBiol. Sciences, N.LH.E., Dublin
9, Eire.
The membrane glycoproteins of malignant cells are
abnormally enriched in large highly sialylated
fucopeptides and incubation of cells with trypsin is
widely used to release these entities. Using
Landschutz ascites tumour we previously showed
that these large fucopeptides are released in
association with the vesicle fraction of cell-free
supernatants. Some release occurs spontaneously
into saline (PBS). This is increased in the presence
of trypsin in association with increased vesiculation.
Fucopeptide size profiles are similar for vesicles
shed under these two conditions. The present study
concerned further examination of these vesicle
fractions released from cells incubated in PBS alone
or containing trypsin (0.1mgml- 1). Metabolic
radioactive labelling showed trypsinate vesicles to
contain more cholesterol ( x 2.5), phospholipid ( x 5)
and fucose (x 1.7) than control vesicles from the
same number of cells. Cholesterol and phospholipid
were also determined chemically. Spontaneous
release of the malignancy-related fucopeptides was
found to be associated with a vesicle fraction
having a cholesterol/phospholipid mole ratio double
that of the bulk plasma membrane, i.e. representing
more rigid domains. In contrast, trypsinate vesicles
gave a ratio similar to that of the plasma
membrane. The association of these glycopeptides
with vesicles indicates that the parent glycoproteins
are integral membrane proteins and that they are
only indirectly sensitive to trypsin.
Fluorescent microscopic studies on the differential
cellular distribution of adriamycin and 4'-
deoxydoxorubicin.
J.A. Plumb, N. Wilmott, D.J. Kerr, A.D. Burt,
I.A.R. More & S.B. Kaye
Department ofMedical Oncology, University of
Glasgow, Glasgow G12 9LX, UK.
The multicellular spheroid was developed as a
system of intermediate complexity between solid
tumours and cell monolayers. Penetration barriers
have been postulated for adriamycin on the basis of
fluorescent microscopic and flow cytometric studies
on spheroids of V79 Chinese Hamster ovary cells.
We have compared the differential distribution of
adriamycin and 4'-deoxy-doxorubicin (4'-deoxy) a
lipophilic derivative, by fluorescent microscopy in
monolayers and spheroids of a human non-small
cell lung tumour and in a solid tumour grown
subcutaneously in rats. At identical drug
concentrations and duration of exposure,
adriamycin bound to cell nuclei whereas 4'-deoxy
was distributed predominantly in a granular fashion
in the cytoplasm with some nuclear binding in cell
monolayers. Ultrastructural studies suggest that 4'-
deoxy might be binding to cytoplasmic lysosomes.
In spheroids from the same cell line adriamycin (5
pgml 1 for 2h)was seen in the nuclei ofthe outer 3-4
cell line layers whereas 4'-deoxy (same
concentration) had penetrated further to a depth of
6-7 cell layers. The drugs were infused (80mgkg- I
over 1 h) via the carotid artery of SP107 adeno-
carcinoma bearing male rats. Fluorescent
microscopy of frozen sections showed a faint ring
of fluorescence on the periphery of the tumour
which corresponded to the position of the majority
of blood vessels (demonstrated by a fluorescent
antibody directed against factor VIII). 4'-deoxy
penetrated further from the outer vascular ring than
did adriamycin. We believe that these data support
the hypothesis that drug penetration barriers exist
for adriamycin and that these may be overcome,
partially by the lipophilic analogue.JOINT MEETING OF THE BACR & IACR 441
Inhibitors of ADP-ribosyl transferase protect against
the cytotoxicity of S-phase acting drugs
K. Moses, A.L. Harris & B.W. Durkacz
Cancer Research Unit, Royal Victoria Infirmary,
Newcastle upon Tyne NE] 4LP, UK.
The synthesis of poly(ADP-ribose) by ADP-ribosyl
transferase (ADPRT) is inhibited by a number of
benzamides. These ADPRT inhibitors enhance the
cytotoxicity of DNA damaging agents and retard
DNA excision repair, without themselves affecting
cell viability. At higher inhibitor concentrations,
cells arrest in GI or G2. We investigated the effects
of 3 ADPRT inhibitors (3-aminobenzamide, 6-
methoxybenzamide and 3-acetamidobenzamide) on
2 S-phase acting drugs, hydroxyurea (HU), and 5
fluoro-2'-deoxyuridine (FUdr). Log-phase CHOKI
cells were preincubated for 8h with inhibitors,
exposed to HU or FUdr for 16h, and plated for
survivors without drugs. All 3 inhibitors reduced
the cytotoxicity of HU and FUdr in a dose
dependent manner. For example, 2mM HU
reduced survival to 1%, but with 20mM 3-
aminobenzamide, survival increased to 50%. A
significant increase in survival was observed with
1 mM 3-aminobenzamide, a concentration 5 x lower
than that used to inhibit DNA excision repair. We
interpret these results as follows: inhibition of
ADPRT results in a reversible cell cycle block in
GI or G2. Cells are prevented from entering S-
phase during exposure to HU or FUdr, thus
alleviating the cytotoxic effects. Of particular
significance is the observation that cell cycle blocks
are detected at concentrations of inhibitors reported
not to affect cell proliferation.
Modulation of transforming growth factor production
in chemically transformed rat glioma cells by
passaging and mitomycin C
A.M. Owsianka, R. Zammit-Pace and J.P. Roscoe
Department ofCell Pathology, School ofPathology,
Middlesex Hospital Medical School, London WIP
7LD, UK.
Tumourigenic cells obtained after induction in rats
by the neurotropic carcinogen, ethylnitrosourea
(Roscoe (1980) Br. Med. Bull., 36, 33), were
examined for production of transforming growth
factor (TGF) activity. The cells were plated in petri
dishes and TGF activity detected by the ability to
induce colony formation in an overlay of rat kidney
cells (NRK 49F) in agar. Several lines produced
significant TGF activity. Surprisingly, the results
showed that some lines produced more TGF
activity at earlier passages than at later passages
when the cells themselves have a higher plating
efficiency in agar. It was also observed that these
later passage cells grew more extensively under the
NRK cells. Treatment with Mitomycin C prior to
overlaying with NRK cells resulted in an
enhancement of TGF production. Small scale
partial purification of conditioned medium from
low passages of a good producer line was carried
out. The material obtained had TGF activity which
was not potentiated by adding epidermal growth
factor. Relative to its ability to induce NRK
growth it was a poor competitor for EGF receptor
binding. Purification of conditioned medium from
high passage cells showed that this had much less
TGF activity which in contrast was potentiated by
EGF. The results showed that TGF production is
altered by passaging and growth inhibition.
Increased plating efficiency of these glioma cells in
agar need not be associated with higher TGF
secretion. However, the cells could still be
producing and responding to their own TGF.